Needham & Company LLC Cuts Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $357.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective lowered by Needham & Company LLC from $510.00 to $357.00 in a report published on Thursday,Benzinga reports. Needham & Company LLC currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities analysts have also issued reports on ALNY. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Wall Street Zen raised Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 25th. Truist Financial reduced their target price on Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating on the stock in a report on Monday, July 13th. Wells Fargo & Company boosted their target price on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the company an “equal weight” rating in a research note on Friday, May 1st. Finally, Citigroup assumed coverage on Alnylam Pharmaceuticals in a report on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $410.72.

Alnylam Pharmaceuticals Stock Up 0.0%

Shares of NASDAQ ALNY opened at $205.52 on Thursday. The stock has a market cap of $27.44 billion, a P/E ratio of 38.20 and a beta of 0.27. The firm has a 50 day moving average price of $287.96 and a 200 day moving average price of $311.32. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13. Alnylam Pharmaceuticals has a 52-week low of $197.81 and a 52-week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating the consensus estimate of $0.87 by $1.12. The firm had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 104.81%. The business’s quarterly revenue was up 96.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.44) earnings per share. Analysts expect that Alnylam Pharmaceuticals will post 7.22 EPS for the current year.

Insider Activity

In related news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director directly owned 1,582 shares in the company, valued at $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. increased its holdings in Alnylam Pharmaceuticals by 20.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 155,695 shares of the biopharmaceutical company’s stock worth $46,869,000 after purchasing an additional 26,799 shares in the last quarter. Parallel Advisors LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 7.9% in the first quarter. Parallel Advisors LLC now owns 891 shares of the biopharmaceutical company’s stock valued at $295,000 after purchasing an additional 65 shares in the last quarter. Glenmede Trust Co. NA lifted its holdings in shares of Alnylam Pharmaceuticals by 8.3% in the first quarter. Glenmede Trust Co. NA now owns 731 shares of the biopharmaceutical company’s stock valued at $242,000 after purchasing an additional 56 shares in the last quarter. Groupama Asset Managment boosted its position in shares of Alnylam Pharmaceuticals by 2.5% during the first quarter. Groupama Asset Managment now owns 36,767 shares of the biopharmaceutical company’s stock worth $12,165,000 after buying an additional 889 shares during the period. Finally, Segall Bryant & Hamill LLC acquired a new position in shares of Alnylam Pharmaceuticals during the first quarter worth about $641,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Chardan Capital reaffirmed its Buy rating and assigned a $425 price target, while JPMorgan, RBC, Oppenheimer, and Stifel maintained bullish ratings despite lowering their targets. The revised targets remain well above the current trading level. Analyst ratings and price targets
• Positive Sentiment: Alnylam reported continued strength in its transthyretin franchise, including record quarterly Amvuttra sales, and revenue increased substantially from the prior-year period. These results support the company’s underlying commercial momentum. Alnylam Q2 2026 earnings call
• Neutral Sentiment: Analysts broadly lowered their targets: JPMorgan cut its target to $375, RBC to $350, Oppenheimer to $350, Stifel to $318, Wells Fargo to $316, and Morgan Stanley to $300. Ratings range from Buy/Outperform to Equal Weight, indicating optimism about valuation but greater near-term uncertainty. Analyst price-target changes
• Negative Sentiment: Second-quarter adjusted earnings of $1.84 per share exceeded some consensus measures but missed the $2.05 Zacks estimate, while revenue of $1.29 billion fell short of the roughly $1.32 billion consensus. Alnylam Q2 earnings miss
• Negative Sentiment: The company cut its 2026 product-revenue outlook to $5.3 billion-$5.7 billion, reflecting normalization in second-line Amvuttra demand and headwinds affecting the ATTR-CM market. The guidance reduction is the primary catalyst behind the stock’s decline. Alnylam lowers 2026 outlook
• Negative Sentiment: Several law firms announced securities-fraud investigations following the results and guidance cut. These announcements may add reputational and legal overhang, although they do not establish wrongdoing. Securities-fraud investigation

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.